A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02326454 |
|
Recruitment Status :
Completed
First Posted : December 29, 2014
Last Update Posted : August 8, 2018
|
Sponsor:
Light Sciences Oncology
Collaborator:
Mundipharma Research Limited
Information provided by (Responsible Party):
Light Sciences Oncology
- Study Details
- Tabular View
- Results Submitted
- FDAAA 801 Violations
- Disclaimer
- How to Read a Study Record
Information on FDAAA 801 Violations
More Information: Notices of Noncompliance [FDA]
| Available on ClinicalTrials.gov | Issued by FDA | Study Record Submitted | Notice Type | FDAAA 801 Notice |
|---|---|---|---|---|
| December 7, 2023 | November 22, 2023 | August 2, 2023 | Issues in letter addressed; confirmed by FDA. | The responsible party has responded, and this matter was resolved administratively. |
| July 31, 2023 | July 19, 2023 | August 6, 2018 | Violation Identified by FDA | Failure to Submit |